transdominant and attenuated hiv-1s: implications for gene therapy.

NLM AIDSLINE Transdominant and attenuated HIV-1s: implications for gene therapy. Jeang KT; Smith S; Huang LM; NIAID, NIH, Bethesda, MD.
December 30, 1994

Int Conf AIDS. 1994 Aug 7-12;10(1):40 (abstract no. 132A). Unique OBJECTIVE: To create altered HIV-1 proviruses, containing foreign genes, capable of autonomous replication with either a transdominant inhibitory phenotype or an attenuated phenotype for pathogenicity. METHODS: Four HIV-1 proviruses separately containing a PKR gene, an HSV-1 thymidine kinase gene, an HTLV-I Tax gene, and a ribozyme gene were created. These proviruses were tested in continuous T-lymphocyte cultures either alone or in co-cultivation with wildtype HIV-1 to assay for attenuated pathogenicity versus transdominant inhibitory properties. RESULTS: We have found that proviruses containing PKR, HSV tk, and ribozyme have capacities to be transdominant inhibitors of wildtype HIV-1. An altered HIV-1 containing HTLV-I Tax showed highly reduced pathogenicity in lymphocyte cultures. DISCUSSION: Attenuated HIVs are potentially useful vaccine candidates. Transdominant HIVs that in themselves have been constructed to be attenuated are useful for therapeutic considerations. Cells, Cultured Gene Therapy Genes, pX Genes, Viral/GENETICS Human HIV Infections/THERAPY HIV-1/GENETICS/PATHOGENICITY HTLV-I/GENETICS Protein-Serine-Threonine Kinases/GENETICS Proviruses/GENETICS T-Lymphocytes/MICROBIOLOGY Thymidine Kinase/GENETICS ABSTRACT

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 CountyCare Offers Historic Opportunity to Improve Care for People with HIV Lawyer: NY man at center of HIV scare not positive GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness UNITED STATES: How Sexual Stigma Is Undermining HIV Treatment on American Indian Reservations HHS Office for Civil Rights launches campaign to increase awareness of HIPAA rights among HIV-positive Black men Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog Living with HIV Global HIV/AIDS leaders meet in SF, Oakland Ugandan youth move to front line of HIV, maternal health fight OVER 7 MILLION PEOPLE NOW RECEIVING HIV TREATMENT IN AFRICA - UN REPORT
Information in this article was accurate in December 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.